

REFERENCES

AASLD (American Association for the Study of Liver Diseases), 2000:

Update on viral hepatitis. Postgraduate Course.

Abdel-Aziz F, Habib M, Mohamed Abdel-Aziz, F.;Habib, M.;Mohamed,M.K.; et al., 2000: Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. *Hepatology*; 32:111-115.

Al Bawaaba 2010. "Highest Rates of Hepatitis C Virus Transmission Found in Egypt". 08-09.

Alter, MJ 2007. "Epidemiology of hepatitis C virus infection". *World journal of gastroenterology* : 13 (17): 2436–41.

Bahtiyar G, Shin JJ, Aytaman A, et al., 2004: Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. *Current Diabetes Reports*; 4:194-198.

Baker DE, 2003: Pegylated Interferon plus Ribavirin for the treatment of chronic hepatitis C. *Reviews in Gastroenterological Disorders* ; 3:93–109.

Bartosch B, Dubuisson J, and Cosset F.L, 2003 “Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes,” *Journal of Experimental Medicine*, vol. 197, no. 5, pp. 633–642.

Bretner M, 2004: Existing and future therapeutic options for hepatitis C virus infection. *Acta Biochemica Polonica*: 52:57-70.

Brunt, E.M.;2001: Nonalcoholic steatohepatitis: Definition and pathology. *Seminars in Liver Disease.*; 21:3-16.

Charlton, M. R, Pockros, P. J and Harrison, S. A, 2006 "Impact of obesity on treatment of chronic hepatitis C," *Hepatology*, vol. 43, no. 6, pp. 1177–1186.

Conjeevaram, H. S., Kleiner, D. E, Everhart J. E. et al., 2007 "Race, insulin resistance and hepatic steatosis in chronic hepatitis C," *Hepatology*, vol. 45, no. 1, pp. 80–87.

Diago M, Hassanein T, Rodes J, et al., 2004: Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. *Annals of Internal Medicine*; 140:72-73.

Dolin, Gerald L. Mandell, John E. Bennett, Raphael 2010. Mandell, Douglas, and Bennett's principles and practice of infectious diseases (7th ed.). Philadelphia, PA: Churchill Livingstone/Elsevier. Chapter 154. Pp: 978-993.

El-Zayadi AR, Selim OE, Hamdy H, et al., 1998: Association of chronic hepatitis C infection and diabetes mellitus. *Tropical Gastroenterology*; 19:141– 144.

Emilio Orfei Loyola, 2005: University of Chicago Stritch School of Medicine Department of Pathology . 44:275–282.

Enomoto N, Sakuma I, Asahina Y, et al., 1996: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *New England journal of medicine*; 334:77-81.

FAQ "Hepatitis C for Health Professionals". Centers for Disease Control and Prevention (**CDC**). Retrieved 2 January 2012.

Foucher J, Chanteloup E, Vergniol J, et al. 2006. "Diagnosis of cirrhosis by transient elastography (FibroScan) . *Gut* **55** (3): 403–8.

- Fried, M.W.;Shiffman, M. L.; Reddy, K.R.;Smith, C.;et al., 2004:**Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *New England journal of medicine*. 347:975-982.
- Ghani MG, Strader DB, Thomas DL and Seeff LB ,2009.** Diagnosis, Management and treatment of Hepatitis C - An Update. *Hepatology*;49:1335-74.
- Goutham, R.A.O (2001):** Insulin resistance syndrome American Academy of Family Physicians, 15:2001,p.(1-7).
- Greub, G; Ledergerber, B; Battegay, M; et al., (1987):** Clinical progression. Survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet*, 356:1800-5.
- Griffin SDC, Beales LP, Clarke DS, et al., 2003:** The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. *Europe Journal of biochemistry* ; 535:34–38.
- Grob PJ, 1998:** Report on working group 2: Austria, Belgium, Bulgaria, Germany, Greece, Hungary, Malta, Russia, Turkey and Uzbekistan. *Vaccine*; 16:61-62.
- Hadziyannis, S.J.;Sette, H. Jr.;Morgan,TR.;Balan, V.; e al., 2004:** Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis .

- Hagan, H; Pouget, ER and Des Jarlais, DC 2011.** "A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs". *The Journal of infectious diseases* 204 (1): 74–83.
- Hahn, J.A.,2007:** "Sex, Drugs, and Hepatitis C Virus". *The Journal of infectious diseases* ;195: 1556-9.
- Halliday, J; Klenerman, P and Barnes, E 2011.** "Vaccination for hepatitis C virus: closing in on an evasive target". Expert review of vaccines 10 (5): 659–72.
- Heller T and Rehermann B, 2005:** Acute hepatitis C: a multifaceted disease. *Seminars in Liver Disease*; 25:7-17.
- Houghton M 2009.** "The long and winding road leading to the identification of the hepatitis C virus". *Journal of Hepatology*51 (5): 939–48.
- Hui JM, Sud A, Farrell GC, et al., 2003:** Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology*; 125:1695-1704.
- Iannuzzella F, Vaglio A and Garini G 2010.** "Management of hepatitis C virus-related mixed cryoglobulinemia". *American Journal of Medicine*. 123 (5):
- Inglot M, Gladys A and Rymer W, 2005:** Experimental therapy in HCV infection. *Przegląd Epidemiologiczny*; 5:525-533.
- Jafari, S; Copes, R, Baharlou, S, Etminan, M and Buxton, J 2010.** "Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis". *International journal of infectious diseases* 14 (11): e928–40.

Karmochkine, M.;Carrat, F.; Dos Santos,O.; Cacoub, P.;Raguin, G., 2006:

A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. *Journal of Viral Hepatology*. 13 (11): 775-82.

Katbamna BH, Petrelli M and Mc Cullough A , 1997:

The liver in diabetes mellitus and hyperlipidemia. In: Gitlin N (Ed). *The Liver and Systemic Disease*. New York, Churchill **Livingstone; 73-113.**

Knobler H, Schihmanter R, Zifroni A, et al, 2000:

Increased risk of type 2 diabetes in non cirrhotic patients with chronic hepatitis C virus infection. *Mayo Clinic Proceedings*; 75:355-359.

Konrad T, Zeuzem S, Vicini P, et al., 2000:

Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. *Europe Journal of Clinical Investigations* ; 30:111-121.

Koshy A, Marcellin P, Martinot M, et al., 2000:

Improved response to ribavirin interferon combination Scompared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. *Liver*; 20:335-339.

Koshy A, Madda JP, Marcellin P, et al., 2002:

Treatment of hepatitis C virus genotype 4-related cirrhosis: Ribavirin and interferon combination compared with interferon alone. *Journal of Clinical Gastroenterology*; 35:82-85.

Kumar V, Fausto N and Abbas A, 2003. Robbins & Cotran Pathologic Basis of Disease (7th ed.). Chapter 7 (Liver, biliary tract and pancreatic disease) pp. 363–4.

Lake-Bakaar G, 2003: Current and future therapy for chronic hepatitis C virus liver disease. *Current drug targets for infectious disorders*; 3:247–253.

Lam, NC; Gotsch, PB and Langan, RC 2010. "Caring for pregnant women and newborns with hepatitis B or C". *American family physician* 82 (10): 1225–9.

Laskus T, 1998: Search for hepatitis C virus extra hepatic sites of replication in patients with acquired immunodeficiency syndrome: Specific detection of negative strand viral RNA in various tissues. *Hepatology*; 28:1398-1401.

Lavanchy, D., 1999: Global Surveillance and Control of Hepatitis C. *Journal of Medical Virology*; 6:35-47.

Lecube A, Hernandez C, Genesca J, et al., 2004: High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. *Diabetes Care*; 27:1171-1175.

Lecube A, Hernandez C, Genesca J, et al., 2006. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. *Diabetes Care*; 29:1140-9.

Legrand-Abravanel F, Nicot F, Boulestin A, et al., 2005: Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. *Journal of Medical Virology*; 77:66-69.

Lindenbach B. D, Evans M. J, Syder A. J, et al., 2005. "Complete replication of hepatitis C virus in cell culture," *Science*, vol. 309, no. 5734, pp. 623–626. View at PubMed ·

Lindsay KL, Trepo C, Heintges T, et al., 2001: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. *Hepatology*; 34:395-403.

Lohmann V, Körner F, Dobierzewska A, et al., 2001: Mutations in hepatitis C virus RNAs conferring cell culture adaptation. *Journal of virology*; 75:1437–1449.

Louie, KS; Micallef, JM, Pimenta, JM, , et al.,2011."Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review". *Journal of viral hepatitis* 18 (1): 1–7.

Maheshwari, A; Ray, S and Thuluvath, PJ 2008."Acute hepatitis C". *Lancet* 372 (9635): 321–32.

Masanori E., Yoshiki N. and Kiyoshi M. (1999): Homeostasis model assessment as a clinical index of insulin resistance in type 2 DM. *Diabetes Care*, Vol. 22. p.(818-822).

Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK and Perrillo RP. 1999: Association of diabetes mellitus and chronic hepatitis C virus infection. *Hepatology* ;29: 328–333.

Mehta SH, Brancati FL, Sulkowski MS, et al., 2004: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Annals of Internal Medicine*; 133:592-599.

Melissa Palmer, M.D., 2004: Guide of Hepatitis and Liver Disease.product.half.ebay.com/_W0QQprZ30449308

Mohamed, M.K., (2004): Epidemiology of HCV in Egypt. *The Afro-Arab Liver Journal*, 3(2):41-52.

Mohamed, M.K.; Abdel-Hamid,M.; Mikhail,N.N.; Abdel-Aziz,F.; et al.,(2005): Intrafamilial transmission of hepatitis C in Egypt. *Hepatology*; 42: 683-687.

Moribe T, Hayashi N, Kanazawa Y, t al., 1995: Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. *Gastroenterology*; 108:789-795.

Mueller, S; Millonig, G and Seitz, HK 2009."Alcoholic liver disease and hepatitis C: a frequently underestimated combination". *World journal of gastroenterology* : 15 (28): 3462–71.

- Muir AJ, Bornstein JD and Killenberg PG, 2004:** Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *New England journal of medicine*; 350:2265-2271.
- Nakano T, Lau GM, Lau GM, Sugiyama M and Mizokami M, 2011.** "An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region". *Liver international journal*. 32 (2): 339–45.
- Nelson, PK; Mather BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D and Degenhardt L, 2011.** "Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews". *Lancet* 378 (9791): 571–83.
- NIH Consensus Statement on Management of Hepatitis C, 2002:** NIH Consensus State Sci Statements 2002; 19: 1-46.
- Oguz D, Cicek B, Filik L, et al., 2005:** Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C genotype 1. *World Journal of Gastroenterology*; 11:580-583.
- Okada S, Akahane Y, Suzuki H, et al., 1992:** The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. *Hepatology*; 16:619-624.
- Ozaras, R and Tahan V, 2009 .**"Acute hepatitis C: prevention and treatment". *Expert review of anti-infective therapy* 7 (3): 351–61.

- Perz, J.F.;Armstrong,G.L.; Farrington,L.A.;et al., 2006:** The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *Journal of Hepatology*; 45: 529-538
- Ploss A, Evans M. J, Gaysinskaya V. A, et al., 2009** “Human occludin is a hepatitis C virus entry factor required for infection of mouse cells,” View at PubMed, *Nature*,vol. 457, no. 7231, pp. 882–886.
- Pondé and RobérioAmorim de Almeida 2011.** "*Hidden hazards of HCV transmission*". *Medical microbiology and immunology* 200 (1): 7–11.
- Poynard T., Bedossa P. and Opolon P., 1997:** Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet*; 349(9055):825-32
- Poynard T, McHutchison J, Manns M, et al., 2002:** Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology*; 122:1303-1313.
- Pozzilli P and Leslie RD, 2004.** Infections, immunity, and diabetes. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P, eds. *International textbook of diabetes mellitus*. Chichester, UK: John Wiley & Sons Ltd,:1729.39.
- Qureshi F, Qureshi F, Anjum Q, et al., 2005:** Is the high frequency of diabetes type 2 in chronic hepatitis C virus infection due to strong family history. *Journal of Ayub Medical College, Abbottabad*; 17:90-91.

Ratziu V, Saboury M and Poynard T, 2003: Worsening of steatosis and fibrosis progression. *Gut*; 52:1386-1387.

Rodríguez-Roisin R, Krowka MJ, Hervé P and Fallon MB 2004. "Pulmonary-Hepatic vascular Disorders (PHD)". *European Respiratory Journal*:24 (5): 861–80.

Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al., 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*;128:636.41.

Rosen, HR 2011. "Clinical practice.Chronic hepatitis C infection". *The New England journal of medicine* 364 (25): 2429–38.

Ross AS, Bhan AK, Pascual M, et al., 2004: Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. *Clin Transplant*; 18:166-173.

Ryan K.J and Ray C.G .,2004:Sherris Medical Microbiology,4th ed., McGraw Hill, pp. 551–2.

Sanyal, AJ , Chand ,N ,Comar, K, et al.,2004. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: A potential mechanism for failure of interferon therapy in subjects with HCV and non-alcoholic fatty liver disease, *Hepatology* ;40:197A.

Sarrazin C, Herrmann E, Bruch K, et al., 2002: Hepatitis C virus nonstructural 5A protein and interferon resistance: a new

model for testing the reliability of mutational analyses. Journal of Virology; 76:11079-11090

Senadhi V, 2011 . "A paradigm shift in the outpatient approach to liver function tests". Southern medical journal 104 (7): 521–5.

Shepard, C.W.;Finelli, L.; Fiore, A.E. and Bell, B.P.; 2005: Epidemiology of hepatitis B and hepatitis C virus infection in United States children. Pediatric Infectious Disease Journal; 24:344-352

Simmonds P, 1999: Viral heterogeneity of the hepatitis C virus. Journal of Hepatology; 31:54-60.

Soriano V, Rodriguez-Rosado R and Garcia-Samananiego J, 1999: Management of chronic hepatitis C in HIV infected patients. AIDS; 13:539-546.

Spada E., Mele A., Ciccozzi, M., Tosti,M.E., et al.,2001: Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Digestive and Liver Disease Journal; 33: 778-784

Springer Verlag. 2011. Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future pp. 103–104.

Strader D.B., Wright T., Thomas D.L., Seeff L.B., 2004: AASLD practice guidelines. diagnosis, management and treatment of hepatitis C. Hepatology; 39:1147-71

Stramer S.L., Glynn S.A., Kleinman S.H., Strong D.M., et al., 2004:Detection of HIV-1 and HCV infections among antibody-

negative blood donors by nucleic acid-amplification testing. *New England journal of medicine*; 351:760-768.

Tarantino, G. . Conca, P, Sorrentino, P and Ariello, M, 2006 “Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis,” *Journal of Gastroenterology and Hepatology*, vol. 21, no. 8, pp. 1266–1268.

Thompson S., Hernberger F., Wale E. and Crofts N., 2006: Hepatitis C transmission through tattooing: a case report. *Australian and New Zealand Journal of Public Health* :20(3):317-8.

Thuluvath PJ and John PR, 2003: Association between hepatitis C, diabetes mellitus, and race. A case-control study. *American Journal of Gastroenterology*; 98:438-441.

Tien PC, 2005: Management and treatment of hepatitis C virus infection in HIV infected adults: Recommendations from the veterans affairs hepatitis C resource center program .

Timm J. ;Neukamm M ;Kuntzen T.;Kim, A. .;et al.,:2007 ,PartnersAIDS Research Center, Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA. *Viral Hepatog.*; 14(5):330-7

Walker, J.H.and Steven, C. (2000): The etiology of type 2 DM. *Diabetographia*, Vol.43, pp.5-7.

Walsh, M. J. Jonsson, J. R.. Richardson, M. M et al., 2006 “Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1,” *Gut*, vol. 55, no. 4, pp. 529–535.

Wilkins, T; Malcolm, JK, Raina, D and Schade, RR 2010. "Hepatitis C: diagnosis and treatment". *American family physician* 81 (11): 1351–7.

World Health Organisation. 1999. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications".

World Health Organization. 2011. Retrieved 2011-07-13.

Zein CO, Levy C, Basu A, et al., 2005: Chronic hepatitis C and type 2 diabetes mellitus: A prospective cross-sectional study. *American Journal of Gastroenterology*; 100:48-55.

Zeuzem S, 2000: Treatment of chronic hepatitis C virus infection in patient with cirrhosis. *Journal of viral Hepatology* ; 7:327-334.

Zeuzem S, 2004: Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well?. *Annals of Internal Medicine*; 140:370-381.

Zignego A.L., Ferri C., Pileri S.A., Caimi P and Bianchi F.B., 2006: for the Italian Association of the Study of Liver (A.I.S.F.) Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. *Dig Liver Dis.*: E-publication.

Zignego AL, Ferri C, Pileri SA, Caimi P and Bianchi FB 2007. "Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach". *Digestive and Liver Disease Journal* 39 (1): 2–17.

Zylberberg H, Chaix MI and Bre´chot C, 2000: Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon alpha. *Annals of Internal Medicine*; 132:845-846.